Yourgene Health PLC CQC accreditation
23 Ottobre 2020 - 8:00AM
RNS Non-Regulatory
TIDMYGEN
Yourgene Health PLC
23 October 2020
Yourgene Health plc
("Yourgene Health" or the "Company")
CQC accreditation
Manchester, UK - 23 October 2020: Yourgene Health (AIM: YGEN), a
leading international molecular diagnostics group, announces that
it has received notification from the Care Quality Commission
("CQC") that the Company's facilities at Citylabs 1.0 in Manchester
are now a second accredited location from which to perform
diagnostics and screening procedures.
The extension of the Company's current CQC registration allows
NIPT testing greater flexibility to operate from both Yourgene
Health locations in Manchester, and confirms that the Company's
COVID-19 testing services meet the demanding standards of the CQC.
As announced on 28 September 2020, the launch of Yourgene Genomic
Services consolidates the Company's established NIPT and rapidly
growing COVID-19 testing services in Manchester and this
accreditation supports this strategy. The CQC registration supports
the Company's continued scale up in capacity for COVID-19 testing
for both private and public market segments.
The CQC is an independent regulator of health and social care in
England and ensures, amongst other things, that services are safe,
high-quality, effective and meet legal standards.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
N+1 Singer (Joint Corporate Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584
391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABLBDGSBDDGGD
(END) Dow Jones Newswires
October 23, 2020 02:00 ET (06:00 GMT)
Grafico Azioni Premaitha (LSE:NIPT)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Premaitha (LSE:NIPT)
Storico
Da Giu 2023 a Giu 2024